This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biotech Stock Mailbag: GTx, Vanda, Pharmacyclics

Johnson & Johnson (JNJ - Get Report) and Pharmacyclics (PCYC - Get Report) submitted ibrutinib to the FDA on Wednesday for the treatment of two blood cancers -- mantle cell lymphoma and chronic lymphocytic leukemia. Ibrutinib has already been hailed as a wonder drug for B-cell lymphomas, so how quickly will FDA approve?

In all seriousness, the speed at which FDA approves ibrutinib will be interesting to watch as a test case for how the agency handles drugs awarded with the breakthrough therapy status, a designation designed to accelerate drug development and approval.

Ibrutinib actually has three breakthrough therapy designations, so investors expect FDA to review the drug and approve it quickly.

Let's try to quantify.

Assuming Pharmacyclics and J&J submitted ibrutinib to FDA on July 10 and the agency grants the drug priority review (eight-month review cycle), the approval would come on March 10, 2014.

No way it's taking that long.

John (above) thinks a three-month review is reasonable, which would place ibrutinib approval on Oct. 10. That's a reasonable expectation, perhaps a tad on the aggressive side.

The fastest recent FDA drug reviews/approvals were Medivation's (MDVN) prostate cancer drug Xtandi (102 days) and Vertex's cystic fibrosis drug Kalydeco (104 days), according to JMP Securities analyst Mike King.

A 102-day review period for ibrutinib would place the approval on Oct. 21. King expects a mid-October approval.

If FDA intends for breakthrough designation to have real meaning, drug reviews should be abbreviated. A three-month review period for ibrutinib sounds right, so call it end of October, early November to be conservative. Certainly, I'd expect ibrutinib to be approved before blood cancer experts gather in New Orleans in the beginning of December for the American Society of Hematology annual meeting.

TheStreet contributor wrote a column in May looking at the implications of an early ibrutinib filing on the value of Pharmacyclics. It's still worth a read.

Here's a chart of Pharmacyclics' performance year to date. The stock is up 15% since the ibrutinib filing was announced. PCYC Chart PCYC data by YCharts

Back to GTX:

GTx has not raised money through a stock offering since June 2011. The company did raise $19 million by selling the breast cancer product Fareston last year.

GTx's CFO Mark Mosteller sold 17,000 shares through the exercise of options on July 8.

And now, for the entertainment portion of the Mailbag: Hate Mail!

Kelvin G. writes, "You are Bleeping wrong about GTXI. I bet you and your crew bought today, Bleep hole."

JT writes, "Your days of slandering companies is over ahole. You will be investigated now! A group is already forming."

Jim: " Bleep hole... bad karma you bleep like you."

Adam (clearly an alias) writes, "Go bleep yourself! You bald headed, ugly bleep , piece of bleep ."

Steve R.: "You really are a dumbass and quite possibly the biggest loser I am proud to say that I don't know."

Enjoy your weekend, all.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
GTXI $0.67 -1.98%
JNJ $99.13 -1.50%
PCYC $255.05 -0.35%
VRTX $116.43 -1.30%
VNDA $9.28 -0.22%


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs